A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adult volunteers. DGX-001 is a peptide being investigated for the treatment of the major depressive disorder. This study will examine the safety and tolerability of increasing doses of DGX-001 and, in an exploratory way, potential moderators and functional markers of its activity.

Timeline

Start

2022-02-24

Primary completion

2022-11-06

Completion

2022-11-06

Drugs

Indications